Main focus: iPSC derived cellular therapies
Company stage: Clinical
Diseases: Parkinson's disease, multiple undisclosed
Genome editing tool: CRISPR-Cas9
Funding stage: Private (acquired, subsidiary of Bayer Pharma)
Location: Cambridge, MA and New York, NY, USA
Partners: Editas Medicine
BlueRock Therapeutics is a company focused on developing stem cell derived therapies. The company applies its research broadly across neurology, cardiology and immunology, with multiple collaborations within these areas. The company has an ongoing technology cross-licensing agreement with Editas Medicine, which allows the company to develop CRISPR-edited stem cell therapies. The company was acquired back in 2019 by Bayer AG.